방사선종양학

본문글자크기
  • 2017년 10월호
    [Oncotarget.] Possible benefits from post-mastectomy radiotherapy in node-negative breast cancer patients: a multicenter analysis in Korea (KROG 14-22).

    서울의대 / 박혜진, 신경환*

  • 출처
    Oncotarget.
  • 등재일
    2017 Mar 15
  • 저널이슈번호
    8(35):59800-59809. doi: 10.18632/oncotarget.16241. eCollection 2017 Aug 29.
  • 내용

    바로가기  >

    Abstract


    PURPOSE:

    This study was performed to identify a subset of patients who may benefit from post-mastectomy radiotherapy (PMRT) among node-negative breast cancer patients.


    MATERIALS AND METHODS:

    We retrospectively reviewed 1,828 patients with pT1-2N0 breast cancer, treated with mastectomy without PMRT from 2005 to 2010 at 10 institutions. Univariate and multivariate analyses for locoregional recurrence (LRR) and any first recurrence (AFR) were performed according to clinicopathologic factors and biologic subtypes.

     

    RESULTS:

    During a median follow-up period of 5.9 years (range: 0.7-10.4 years), 98 patients developed AFR (39 isolated LRR, 13 LRR with synchronous distant metastasis, and 46 isolated distant metastasis), and 52 patients developed LRR. The 7-year LRR and AFR rates were 3.8% and 6.7%, respectively. Multivariate analysis revealed that age of ≤ 40 years (p<0.001) and T2 stage (p=0.013) were independent risk factors for LRR. The 7-year LRR rates were 2.5% with no risk factors, 4.5% with one risk factor, and 12.4% with two risk factors. Multivariate analysis for AFR revealed that age of ≤ 40 years (p<0.001), T2 stage (p<0.001), and triple-negative biological subtype (p=0.045) were independent risk factors for AFR. The 7-year AFR rates were 3.9% with no risk factors, 8.4% with one risk factor, and 15.7% with two to three risk factors.


    CONCLUSIONS:

    Mastectomy without PMRT is a sufficient local treatment for pT1-2N0M0 breast cancer. Nevertheless, PMRT might be considered for patients with two or three risk factors, among those of young age, with T2 tumors, and with the triple-negative biological subtype based on LRR and AFR.​

     

    Author information

    Park HJ1, Shin KH2, Kim JH3, Ahn SD4, Kim SS4, Kim YB5, Park W6, Kim YJ7, Shin HS8, Kim JH9, Lee SY10, Kim K11, Park KR12, Jeong BK13.

    Departments of Radiation Oncology, Hanyang University Hospital, Seoul, Korea.

    Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Korea.

    Department of Radiation Oncology, Seoul National University Hospital, Seoul, Korea.

    Department of Radiation Oncology, University of Ulsan College of Medicine, Seoul, Korea.

    Department of Radiation Oncology, Yonsei University College of Medicine, Seoul, Korea.

    Department of Radiation Oncology, Sungkyunkwan University School of Medicine, Seoul, Korea.

    Department of Radiation Oncology, Proton Therapy Center, National Cancer Center, Goyang, Korea.

    Department of Radiation Oncology, CHA University School of Medicine, Pocheon, Korea.

    Department of Radiation Oncology, Keimyung University School of Medicine, Daegu, Korea.

    10 Department of Radiation Oncology, Chonbuk National University Hospital, Jeonju, Korea.

    11 Department of Radiation Oncology, Ewha Womans University School of Medicine, Seoul, Korea.

    12 Department of Radiation Oncology, Ewha Womans University Mokdong Hospital, Seoul, Korea.

    13 Department of Radiation Oncology, Gyeongsang National University School of Medicine, Jinju, Korea.

     

  • 키워드
    breast cancer; post-mastectomy radiotherapy; risk factors
  • 덧글달기
    덧글달기
       IP : 18.116.90.141

    등록